This cohort study compares risks of thromboembolic stroke, intracranial hemorrhage, major extracranial bleeding, and mortality in Medicare beneficiaries with nonvalvular atrial fibrillation who initiated dabigatran or rivaroxaban therapy for stroke prevention.
This structured review identifies and highlights the 10 original research articles most likely to reduce overuse of medical care.
In this single-center study of asymptomatic patients with atrial fibrillation, the yield for detecting ischemia with myocardial perfusion imaging was low and did not significantly increase with increasing clinical risk.
This systematic review assessed the safety and procedural success of the Lariat device, and the investigators found significant risks of major adverse events with off-label use for left atrial appendage exclusion.
This cross-sectional study demonstrates that opioid use is associated with an increased prevalence of atrial fibrillation.
This study examines the change in proportion of atrial fibrillation patients eligible for anticoagulation before and after the 2014 revision of the AHA/ACC/HRS anticoagulation guidelines.
This retrospective cohort study reports a higher incidence of major bleeding and a higher risk of gastrointestinal bleeding with dabigatran.
Albrecht et al estimate the risk of thrombotic and hemorrhagic events associated with warfarin therapy resumption following traumatic brain injury.